Scan the QR code on any vial to verify its batch, COA, and origin in seconds. Secure traceability from our lab to your bench.
Drag to rotate
The Eon standard
High Purity Guarantee
Your results are only as good as your compound. Every lot of BPC-157 / TB-500 is tested by an independent ISO/IEC 17025-accredited lab in the USA. 99%+ purity isn't a target here. It's the requirement. Don't take our word for it: test any vial at an accredited lab of your choice. If HPLC purity comes back under 99%, we refund your order and pay for the test.
Size
20mg
Purity
99%+ by HPLC · guaranteed
Identity
Confirmed by mass spec
Lab
Accurate Test Labs · ISO/IEC 17025
About this compound
This is a blend. BPC-157 and TB-500 are combined in a single 20 mg vial. Both appear in tissue remodelling research, but they work through different routes. BPC-157 has been studied at growth factor pathways, while TB-500 has been studied at actin, a protein that gives cells their shape and allows them to move. Researchers use blends to compare combined conditions against single compounds.
Dual-peptide blend: BPC-157 (15-aa pentadecapeptide) + TB-500 (43-aa active fragment of Thymosin Beta-4)
The numbers that define BPC-157 / TB-500 and how it is being studied. For laboratory research use only.
2
Synergistic Pathways
VEGF + Actin regulation
7×
GHR Upregulation (BPC-157)
Tendon fibroblast culture, day 3
2-3×
Cell Migration (TB-500)
Keratinocytes in a Boyden chamber assay
4
Research Areas
Tendon & Ligament
Wound Closure
Vascular Models
How It Works
How BPC-157 / TB-500 works
The pathways BPC-157 / TB-500 acts on - and what each one does. The animation traces its signal outward from the compound to every target it engages.
Signalling pathways studied in preclinical models · illustrative
Angiogenesis & Cytoprotection
BPC-157
Raised VEGF expression and new vessel formation have been measured for BPC-157, alongside perfusion of the surrounding tissue. NO system activity and cytoprotective endpoints are also characterised.
VEGF-mediated angiogenesis
Nitric oxide system modulation
Gastric and tissue cytoprotection
Cell Migration & Actin Regulation
TB-500
TB-500 sequesters G-actin monomers, with cytoskeletal remodelling and cell migration toward injury sites measured. Integrin-linked kinase (ILK) signalling is also characterised.
Actin-mediated cell migration
Integrin-linked kinase activation
Anti-fibrotic remodeling
Complementary Pathways
Synergy
BPC-157 is characterised on vascular endpoints (perfusion at the injury site), TB-500 on cell mobilisation to the same site. The two cover distinct pathways - perfusion and cellular migration.
Perfusion endpoints (BPC-157)
Phase 2: Cell mobilization (TB-500)
Combined anti-inflammatory effects
Uses & Applications
What BPC-157 / TB-500 is researched for
The main areas BPC-157 / TB-500 is being studied for - and the study-reported figures behind them.
Musculoskeletal
Tendon & Ligament
BPC-157 is studied in tendon models while TB-500 is characterised for cell migration toward the injury site; the pairing is investigated as a combined condition.
Dermatology
Wound Closure Models
TB-500 is studied in dermal and scarring models; BPC-157 for vascular endpoints including perfusion at wound sites.
Cardiovascular
Vascular Models
Angiogenesis via the NO system is measured for BPC-157; cardiac cell migration through ILK activation for TB-500.
Anti-Inflammatory
Inflammatory Signalling
Anti-inflammatory endpoints are measured for both peptides through distinct mechanisms.
Study-reported magnitudes
Representative figures from published research. Bars fill as you scroll.
BPC-157 Tendon Remodelling72%
TB-500 Cell Migration85%
BPC-157 GHR Expression700%
TB-500 Wound Closure61%
Figures are representative of published research findings and shown for reference.
Molecular Structure
The BPC-157 / TB-500 molecule
An interactive 3D model rendered from the compound record - rotate and explore its structure.
Molecular model
Sequence length
blend
Physical form
Lyophilized powder blend
Documented purity
≥99% by HPLC
Compound Information
Full specification
Components
BPC-157 + TB-500 (Thymosin Beta-4)
BPC-157 Sequence
15 amino acids (Gly-Glu-Pro-Pro-Pro...)
TB-500 Fragment
43-amino acid active region of Tβ4
Form
Lyophilized powder blend
Purity
≥99% per component (HPLC verified)
Testing
Third-party HPLC, Mass Spec, Endotoxin
Storage
-20°C for long-term stability
Solubility
Water-soluble
COA
Included with every order
Strength
20mg
Purity (HPLC)
>99% (HPLC)
Appearance
White to off-white powder
Stability
24 months from manufacture date when stored properly
FAQ
Common questions about BPC-157 / TB-500
BPC-157 and TB-500 act through complementary mechanisms. Vessel formation (angiogenesis) and perfusion are measured for BPC-157; cell mobilisation via actin regulation for TB-500. The pairing covers vascular and cellular-migration pathways.
No. The combination has not been characterised as a single formulation. The rationale is based on complementary mechanisms described for each component individually in preclinical models.
No. Neither BPC-157 nor TB-500 is FDA approved for any indication. This blend is sold exclusively for in vitro laboratory research purposes and is not intended for human consumption.
Store lyophilized at -20°C for long-term stability, protected from light and moisture, and avoid repeated freeze-thaw cycles. Both components maintain stability under standard peptide storage conditions.
Each component undergoes independent third-party testing including HPLC for purity verification, mass spectrometry for molecular weight confirmation, and endotoxin testing. A Certificate of Analysis is included with every order.
Research Use Only.
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.
